Literature DB >> 22483472

Cytomegalovirus viremia after kidney transplantation in Thailand: predictors of symptomatic infection and outcome.

S P Watcharananan1, S Louhapanswat, W Chantratita, S Jirasiritham, V Sumethkul.   

Abstract

BACKGROUND: While prevention of cytomegalovirus (CMV) infection after kidney transplantation (KT) has become a standard practice in Western countries, this approach is not always feasible in Thailand. In order to argue for the need for CMV prevention, the knowledge on the incidence and impact of the CMV infection following KT is highly desirable.
METHODS: We retrospectively reviewed medical records of adult patients who underwent KT at our transplant center between January 2006 and December 2010. Patients who developed CMV viremia within 1 year after transplantation were studied for the incidence, risk factors, and outcome of symptomatic infection. The threshold value of blood CMV DNA load indicating symptomatic infection was also analyzed.
RESULTS: Symptomatic CMV infection occurred in 18 (4.6%) patients within a median time of 12.1 (range, 3-30) weeks after KT. At initial presentation, coexisting opportunistic infection was common (44%) and gastrointestinal tract was the major type of organ involvement (44%). Between groups of patients with symptomatic and asymptomatic CMV infection, the mean (± standard deviation) level of blood viral load were significantly higher in the first group [4.2 (± 0.5) vs 3.3 (± 0.4) log copies/mL]. From multivariate analysis, associated factors of symptomatic infection included acute rejection [odds ratio (OR) 7.32, P = 0.001], and acute tubular necrosis (OR 3.44, P = .019). Death (13%) and graft failure (13%) were significantly higher among the symptomatic infection group than those in the no-infection group (P = .005 and .03, respectively).
CONCLUSION: Despite a low incidence rate, symptomatic CMV infection clearly resulted in significant morbidity following KT. In Thailand, the prevention of CMV infection should be prioritized among high-risk KT populations.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22483472     DOI: 10.1016/j.transproceed.2011.12.029

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country.

Authors:  Kritsada Pongsakornkullachart; Methee Chayakulkeeree; Attapong Vongwiwatana; Wannee Kantakamalakul; Peenida Skulratanasak; Pakpoom Phoompoung
Journal:  Front Cell Infect Microbiol       Date:  2022-05-12       Impact factor: 6.073

2.  Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study.

Authors:  Maria N Chitasombat; Siriorn P Watcharananan
Journal:  F1000Res       Date:  2018-09-28

3.  Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Narisa Ruenroengbun; Tunlanut Sapankaew; Kamolpat Chaiyakittisopon; Pakpoom Phoompoung; Thundon Ngamprasertchai
Journal:  Front Cell Infect Microbiol       Date:  2022-04-01       Impact factor: 6.073

4.  A Nationwide Survey of Cytomegalovirus Prevention Strategies in Kidney Transplant Recipients in a Resource-Limited Setting.

Authors:  Jackrapong Bruminhent; Asalaysa Bushyakanist; Surasak Kantachuvesiri; Sasisopin Kiertiburanakul
Journal:  Open Forum Infect Dis       Date:  2019-07-08       Impact factor: 3.835

5.  Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity.

Authors:  Similan Kirisri; Apirom Vongsakulyanon; Surasak Kantachuvesiri; Raymund R Razonable; Jackrapong Bruminhent
Journal:  Open Forum Infect Dis       Date:  2021-04-17       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.